Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 7/23/2024 | $80.00 | Buy | H.C. Wainwright |
| 1/29/2024 | $38.00 → $40.00 | Neutral → Overweight | JP Morgan |
| 12/15/2023 | $35.00 | Buy → Neutral | BofA Securities |
| 12/8/2023 | $75.00 → $30.00 | Buy → Hold | Jefferies |
| 10/20/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 10/20/2023 | $75.00 → $20.00 | Outperform → Market Perform | Leerink Partners |
| 3/21/2023 | $37.00 | Mkt Perform | Bernstein |
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the com
U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Submitted for Presentation at the American Society of Hematology (ASH) Annual Meeting First Patient Dosed in the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD); Initial Clinical Data Expected in 2025 Ended Second Quarter 2024 with $1.0 Billion in Cash, Cash Equivalents and Marketable Securities; Expected Operating R
CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor. "Terry-Ann has been an invaluable member of our team over the last five years, and her leadership was instrumental in the success of our IPO, the build-out of our finance and corporate affairs functions, and the development of Be
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the com
Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam's Opt-In Rights to Verve Therapeutics' Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development-Stage Payments GMP Operations Initiated at Beam's North Carolina Manufacturing Facility Strong Balance Sheet Provides Anticipated Operating Runway into the Second Half of 2026 CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, to
Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned Initiation of BEAM-101 Clinical Trial and IND Submission for BEAM-102 in the Second Half of 2022 Strong Cash Position of $1.2 Billion, Including Pfizer Upfront, to Support Robust Set of Milestones Across Ex Vivo and In Vivo Base Editing Programs Anticipated in 2022 and Beyond CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced pipeline and business highlights,
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday. Shares of Danaher Corporation (NYSE:DHR) rose sharply during Tuesday's session after the company reported better-than-expected second quarter earnings. Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from Benzinga Pro. Danaher shares gained 7.4% to $269.35 on Tuesday. Here are some other big stocks recording gains in today’s session. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares jumped 16% to $24.81 af
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $80.
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
Scotiabank initiated coverage of Beam Therapeutics with a rating of Sector Outperform
H.C. Wainwright initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $80.00
JP Morgan upgraded Beam Therapeutics from Neutral to Overweight and set a new price target of $40.00 from $38.00 previously
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO). Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities. Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam's research, manufacturing, regulatory, quality and pharmaceutical sciences organizations. "We are thrilled to welcome Gopi to the Beam team during this exciting time a
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. "We are thrilled to welcome John and Jen to the ProKidney Board. They each have a wealth of experience t
10-Q - Beam Therapeutics Inc. (0001745999) (Filer)
8-K - Beam Therapeutics Inc. (0001745999) (Filer)
8-K - Beam Therapeutics Inc. (0001745999) (Filer)